Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia

Yifeng Xia a,b,1, Jingnan An c,1, Jiaying Li d, Wenxing Gu a, Yifan Zhang a, Songsong Zhao a, Cenzhu Zhao c, Yang Xu c,1, Bin Li d, Zhiyuan Zhong a,b,**, Fenghua Meng a,b,**

a Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123, PR China
b College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, PR China
c Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215123, PR China
d Orthopedic Institute, Soochow University, Suzhou, 215007, PR China

ARTICLE INFO

Keywords:
Polymersomes
Targeted delivery
Acute myeloid leukemia
Polo-like kinase 1
Molecular targeted drug

ABSTRACT

Acute myeloid leukemia (AML) remains a most lethal hematological malignancy, partly because of its slow development of targeted therapies compared with other cancers. PLK1 inhibitor, volasertib (Vol), is among the few molecular targeted drugs granted breakthrough therapy status for AML; however, its fast clearance and dose-limiting toxicity greatly restrain its clinical benefits. Here, we report that transferrin-guided polymersomes (TPs) markedly augmented the targetability, potency and safety of AML. Vol-loaded TPs (TPVol) with 4% transferrin exhibited best cellular uptake, effective down-regulation of p-PLK1, p-PTEN and p-AKT and superior apoptotic activity to free Vol in MV-4-11 leukemic cells. Intravenous injection of TPVol gave 6-fold higher AUC than free Vol and notable accumulation in AML-residing bone marrow. The efficacy studies in orthotopic MV-4-11 leukemic model demonstrated that TPVol significantly reduced leukemic cell proportions in periphery blood, bone marrow, liver and spleen, effectively enhanced mouse survival rate, and impeded bone loss. This transferrin-guided nano-delivery of molecular targeted drugs appears to be an interesting strategy towards the development of novel treatments for AML.

1. Introduction

Acute myeloid leukemia (AML) remains one of the most lethal hematological malignancies [1]. AML is characterized by lacking specific antigens, which hinders the clinical development of targeted therapies such as antibodies, antibody-drug conjugates, and CAR-T cell therapy [2]. It is reported that ca. 40% remitted AML patients would eventually relapse and become refractory to treatments [3]. The advancement of molecular targeted drugs has revolutionized the therapeutic scheme for various hematological and solid tumors [4,5], as they possess not only better specificity and anti-cancer activity but also less off-target toxicity than traditional chemical agents [6,7]. The analyses of clinical AML samples have shown that 60% AML patients overexpress polo-like kinase 1 (PLK1) [8], for which a variety of PLK1 inhibitors such as volasertib (Vol) and onvansertib have been designed and clinically investigated for treating AML patients [9,10]. Notably, Vol as a lead agent has demonstrated significant clinical efficacy in AML patients [11,12] and has been granted breakthrough therapy status by FDA. However, as most small molecular drugs, Vol suffers from fast clearance, low bioavailability, and frequent and high dosing that induce dose-limiting toxicities such as...
megakaryocyte dysmaturity and severe thrombopenia, thus greatly restraining clinical benefits [13].

Targeted delivery with nanomedicines provides a potential strategy for improving the efficacy of molecular drugs [14,15]. Many cancers including AML are found expressing high levels of transferrin receptor, which has stimulated the development of various transferrin-guided nanosystems [16]. Chang et al. reported that anti-transferrin receptor single-chain antibody fragment-mediated nanodelivery of tumor suppressor gene p53 could target metastatic lesions and induce clinical anticancer effects [17]. Unlike antibodies and antibody fragments, transferrin as an endogenous protein is not immunogenic. Huang et al. reported that transferrin conjugated lipopolyplex nanoparticles could significantly increase the therapeutic effect of decitabine and showed excellent potential in AML treatment [18]. It is extremely challenging, nevertheless, to prepare transferrin-guided systems for molecular targeted drugs like Vol because few vehicles can stably load Vol and allow post-modification with transferrin.

Here, we report that transferrin-guided polymersomes (TPs) markedly augment the targetability, potency and safety of Vol to AML (Scheme 1). The chimaeric polymersomes with dithiolane-functionalized polycarbonate as membrane, poly(ethylene glycol) as outer shell and poly(aspartic acid) as inner shell were shown to efficiently encapsulate and deliver Vol to ovarian cancers [19]. Transferrin was conjugated to Vol-loaded polymersomes with controlled density via click chemistry. Notably, PVol with 4% transferrin (TPVol) exhibited best cellular uptake, effective down-regulation of p-PLK1 and p-PTEN, and significant survival benefits in highly malignant MV-4-11 leukemic model. Transferrin-targeted delivery of clinical PLK1 inhibitor appears to be an attractive strategy for treating AML.

2. Experimental section

2.1. Preparation of volasertib-loaded transferrin-guided polymersomes (TPVol)

TPVol was prepared by post-modification of azide-functionalized polymersomal Vol (N3-PVol) with DBCO modified transferrin (Tf-DBCO) via click chemistry. To prepare N3-PVol, 100 μL DMSO solution of PEG-(TMC-DTC)-PAsp (as reported in Ref. [20]) (40 mg/mL), N3-PEG-(TMC-DTC) (as reported in Ref. [21]) (2–8 mol% with respect to PEG-(TMC-DTC)-PAsp), and volasertib (Vol, 4 mg) was added under stirring into HEPES buffer (pH 6.8, 5 mM, 0.9 mL). The resulting dispersion was incubated at 37 °C for 2 h in a shaking bath (200 rpm) and then dialyzed against HEPES (pH 7.4, 5 mM) for 6 h (MWCO 14000 Da).

To prepare Tf-DBCO, 41 μL of DBCO-ÖEG4-NHS solution (10 mg/mL) in DMSO was added into 2 mL of Tf solution (20 mg/mL) in MiliQ water (Tf/DBCO molar ratio of 1/1.2) followed by reaction at 37 °C in shaking bath (200 rpm). After 12 h, the mixture was subject to ultrafiltration (MWCO 10 kDa) for 3 times. The final Tf concentration was determined by BCA kit, and the DBCO functionality of Tf-DBCO was determined by MALDI-TOF mass spectrometry.

TPVol was prepared by adding freshly prepared Tf-DBCO into N3-PVol solution at a Tf-DBCO/N3-PVol molar ratio of 1.8/1 under stirring, reacting for 12 h under shaking (100 rpm, 37 °C), and purified via ultrafiltration (Millipore, MWCO 1000 kDa). The non-targeted formulation, PVol, was prepared similarly as for N3-PVol from PEG-(TMC-DTC)-PAsp and Vol. The size distribution and Vol loading content of TPVol and PVol were determined. The morphology of PVol was determined by cryo-TEM. The stability of TPVol and PVol at 4 °C, against 10% FBS, or under 10 mM GSH was monitored using DLS. Besides determination using BCA protein assay kit, the Tf content on TPVol was also quantified using fluorometry. Briefly, TPVol with unknown Tf content was incubated with excess rabbit anti-human Tf antibody for 15 min followed by twice centrifugal ultrafiltration (MWCO: 1 MDa). Then Alexa Fluor™ 647-labeled goat anti-rabbit IgG secondary antibody was added to incubate for 15 min following the same purification procedure. Then polymersome solution was 20-fold diluted to measure the fluorescence intensity. The Tf content on TPVol could be determined based on a standard curve of Alexa Fluor™ 647-labeled secondary antibody.

2.2. Hemolytic analysis

Mouse blood (2 mL) was washed three times with 8 mL sterile PBS.
The red cell suspensions after 9-fold dilution with sterile PBS were incubated for 3 h with TPVol, PVol or Vol solutions (Triton solution and pure water as positive controls) and centrifuged at 150 × g for 5 min. The supernatants were taken for UV-vis measurements (at 545 nm).

2.3. Transferrin receptor (TfR) expression on AML cell lines and patient primary cells

Bone marrow (BM) samples were collected from four AML patients for determining TfR expression and the effect of TPVol on cell growth inhibition and apoptosis of primary cells, which were approved by the ethics committee of the First Affiliated Hospital of Soochow University (Suzhou, P.R. China) in accordance with the Declaration of Helsinki protocol.

To determine the TfR expression, patient primary cells and AML cell lines (MV-4-11, U937) and ALL-697 in EP tubes (5 × 10⁵ cells) were washed (PBS, × 2), resuspended in 100 μL PBS, and stained with APC anti-TfR antibody for 15 min under dark at room temperature. 300 μL PBS was added before flow cytometry analysis (10,000 cells were gated) and MV-4-11 cells without staining were set as negative control.

2.4. Cell apoptosis and cell cycle arrest of TPVol

To evaluate the apoptotic activity, MV-4-11 cells, U937 cells and AML primary cells with high TfR expression (#20210618) and low TfR expression (#20200903 and #20210816) seeded in 6-well plates (3 × 10⁵ cells/well) were incubated with TPVol, PVol or free Vol (Vol conc.: 0.07 μg/mL) for 48 h. The cells were centrifuged, washed, and resuspended in binding buffer before staining with annexin V-Alexa Fluor 647/propidium iodide (PI) under dark for 15 min. Finally, 400 μL binding buffer was added and the cells were measured using flow cytometry.

To investigate cell cycle arrest, MV-4-11 cells in 24-well plates (2 × 10⁵ cells/well) were added with TPVol, PVol or free Vol (Vol conc.: 0.07 μg/mL). After incubation for 48 h, cell cycle kit (Fcmacs) was applied and subject to flow cytometry measurement and analysis using FlowJo software.

2.5. Cell growth inhibition of AML patient primary cells by TPVol

The growth inhibition of patient primary cells was evaluated using trypan blue rejection method. The primary cells with high TfR expression (#20210618) and low TfR expression (#20200903 and #20210816) were cultured in 96-well plates (1 × 10⁵ cells/well) were incubated with TPVol, PVol or free Vol (Vol conc.: 0.07 μg/mL) and cultured for 48 h. Trypan blue solution (0.4%) was added to stain the dead cells, and the cells were counted and stained with an inverted microscope.

2.6. Pharmacokinetics

All animal experiments were approved by the Animal Care and Use Committee of Soochow University (P.R. China), and all protocols conformed to the Guide for the Care and Use of Laboratory Animals. FITC-labeled Vol (Vol-FITC) was prepared by amidation reaction [22], and loaded into polymersomes for studying the pharmacokinetics. PVol-FITC or TPVol-FITC (Vol: 6 mg/kg (mpk), FITC: 0.8 mpk) in 200 μL PB was intravenously injected into healthy Balb/c mice via tail veins (n = 3). At preset time points, ca. ~70 μL blood was withdrawn, treated and analyzed as reported [23] and detailed in supporting information.

2.7. In vivo targeting and fluorescence imaging

To build orthotopic MV-4-11-Luc-GFP AML mouse model, six-week-old female NSG mice (22–24 g) were irradiated with 175 cGy X-ray and 6 h later intravenously injected with 0.02 mL of MV-4-11-Luc-GFP cells (1 × 10⁵). The AML progression was monitored in vivo imaging system on day 6 and 12 post tumor inoculation and the AML infiltration into the major organs and bone marrow were evaluated using flow cytometry.

To assess the targetability and biodistribution of TPVol in orthotopic AML model, on day 13 after tumor inoculation, a single injection of Cy5-labeled TPVol or PVol in 200 μL PB was i.v. administered (Vol: 6 mpk, Cy5: 0.05 mpk). After 8 h, major organs and limb bones of the mice were collected and ex vivo imaged using IVIS system (Living Image 2.6 software).

2.8. In vivo anti-AML efficacy in orthotopic MV-4-11 model

The orthotopic AML model was established as above and 5 days after tumor inoculation the bioluminescence was ca. 5 × 10⁵ p/sec/cm²/sr, the mice were divided into six groups (n = 7) and the day was denoted day 0. On day 0, 2, 4 and 6, free Vol, PVol, 2%TPVol, 4%TPVol (dose: 6 mpk) and PBS were i.v. injected. For 4%TPVol, we also adopted a different dosing regimen, in which 4%TPVol was i.v. administrated on day 0, 3, 6 and 9 at a dose of 9 mpk. The body weight was monitored every two days and normalized to the initial weight on day −1. On day 0, 3, 6 and 9, the mice were in vivo imaged to track the tumor progression using IVIS imaging system. The survival curves of mice were recorded, and those with body weight loss over 15% were also consider dead.

2.9. Flow cytometry, histological and μCT analyses of mice treated with Vol formulations

The AML mice were treated with PBS, free Vol, PVol, or 4%TPVol (6 or 9 mpk) as described above (n = 3). On day 9 the mice were sacrificed and peripheral blood (PB), liver, spleen, hind femur and tibia were collected for AML cell infiltration and histological analysis. To determine the AML cell infiltration, PB, part of liver, spleen, and hind limbs were grinded and filtrated to get cell suspension. The cells were centrifuged (600 × g, 5 min) and treated with 5 mL ACK lysis buffer at 4 °C for 5 min and terminated with 10 mL PBS. The cells were then labeled using anti-CF45-APC for flow cytometric analyses. Moreover, aliquots of cells collected from bone marrow were subject to lysis by ice-cold RIPA buffer for western blot measurements for the expression of PLK1, p-AKT, AKT using GAPDH as reference protein (supporting information), and the gels were further semi-quantified using ImageJ software.

μCT (SkyScan 1176, Belgium) was used to measure and quantitatively analyze hind femurs and tibia using NRecon software. The slices of main organs and leg bones were stained with tartrate resistant acid phosphatase (TRAP, Servicebio, China) and observed using Olympus BX41 microscope for determining tissue damage, leukemic infiltration and osteoclast formation.

2.10. Statistical analysis

Data were expressed as mean ± s.d. Differences among groups were evaluated using one-way Anova and Tukey multiple comparison test or student t-test. Survival curves were evaluated using Kaplan-Meier and log-rank comparison test using Graphpad Prism 8. *p < 0.05 was significant, and **p < 0.01, ***p < 0.001, ****p < 0.0001 highly significant.

3. Results and discussion

3.1. Preparation of TPVol

Lack of potent and safe molecular targeted drugs is one of the main reasons for little survival improvement of AML patients over the past decades. Here, targeted delivery of clinical PLK1 inhibitor, Vol, was proposed as a novel strategy to enhance the efficacy as well as safety of targeted molecular therapy for AML. The disulfide-crosslinked
chimaeric polymersomes are one of the few systems that could stably load Vol [19]. To target AML, we further modified Vol-loaded polymersomes (PVol) with transferrin by click chemistry. Firstly, Vol-loaded chimaeric polymersomes (PVol) with transferrin by click chemistry. Firstly, Vol-loaded chimaeric polymersomes (PVol) with transferrin by click chemistry. Firstly, Vol-loaded chimaeric polymersomes (PVol) with transferrin by click chemistry.

Table 1: Characterization of TPVol obtained by post-modification at a Tf-DBCO/N3 molar ratio of 1.8/1.

| Entry | N3 Surface Density (mol.%) | Size (nm) | PDI | DLCa (wt.%) | DLEC (wt.%) |
|-------|---------------------------|-----------|-----|--------------|--------------|
| 1     | 48.1 ± 0.14 ± 0.03        | 5.0       | 52.1|
| 2     | 48.9 ± 0.15 ± 0.02        | 4.9       | 51.2|
| 3     | 49.4 ± 0.16 ± 0.03        | 5.1       | 53.5|
| 4     | 50.9 ± 0.16 ± 0.02        | 4.9       | 52.0|

a Measured by DLS using a Zetasizer Nano-ZS at 25 °C in PB (10 mM, pH 7.4).

b Determined by UV-vis measurements.

cytotoxic to normal cells than free Vol.

3.2. In vitro cellular uptake, cytotoxicity and blockage of PLK1 signaling

Transferrin receptors (TfR) are overexpressed on several malignant tumors in patients, and TfR-targeting nano-formulations have advanced to clinical trials for treating lung, breast and ovarian cancers [25,26]. TfR was also found highly upregulated in AML cells [18], and 57% AML patients overexpress TfR [27]. FACS analyses confirmed that MV-4-11 and U937 cell lines have high TfR expression while low TfR expression was observed on 697 cells (Fig. 1 A). Cellular uptake studies using Cy5-labeled TPVol and PVol showed clearly enhanced internalization of TPVol by MV-4-11 cells and TPVol with 4% Tf appeared to be the best (Fig. 2 B). CLSM images showed that TPVol and PVol caused significantly less hemolysis than free Vol and pure water, indicating excellent biocompatibility. MTT assays in L929 fibroblasts revealed that both TPVol and PVol were essentially non-toxic at a concentration of 40 μg Vol equiv./mL, whereas free Vol caused significant cytotoxicity (Fig. 1 G). These results confirm the biocompatibility, stability and cytotoxicity of TPVol.

Table 1: Characterization of TPVol obtained by post-modification at a Tf-DBCO/N3 molar ratio of 1.8/1.

| Entry | N3 Surface Density (mol.%) | Size (nm) | PDI | DLCa (wt.%) | DLEC (wt.%) |
|-------|---------------------------|-----------|-----|--------------|--------------|
| 1     | 48.1 ± 0.14 ± 0.03        | 5.0       | 52.1|
| 2     | 48.9 ± 0.15 ± 0.02        | 4.9       | 51.2|
| 3     | 49.4 ± 0.16 ± 0.03        | 5.1       | 53.5|
| 4     | 50.9 ± 0.16 ± 0.02        | 4.9       | 52.0|

a Measured by DLS using a Zetasizer Nano-ZS at 25 °C in PB (10 mM, pH 7.4).

b Determined by UV-vis measurements.

cytotoxic to normal cells than free Vol.

3.2. In vitro cellular uptake, cytotoxicity and blockage of PLK1 signaling

Transferrin receptors (TfR) are overexpressed on several malignant tumors in patients, and TfR-targeting nano-formulations have advanced to clinical trials for treating lung, breast and ovarian cancers [25,26]. TfR was also found highly upregulated in AML cells [18], and 57% AML patients overexpress TfR [27]. FACS analyses confirmed that MV-4-11 and U937 cell lines have high TfR expression while low TfR expression was observed on 697 cells (Fig. 1 A). Cellular uptake studies using Cy5-labeled TPVol and PVol showed clearly enhanced internalization of TPVol by MV-4-11 cells and TPVol with 4% Tf appeared to be the best (Fig. 2 B). CLSM images showed that TPVol and PVol caused significantly less hemolysis than free Vol and pure water, indicating excellent biocompatibility. MTT assays in L929 fibroblasts revealed that both TPVol and PVol were essentially non-toxic at a concentration of 40 μg Vol equiv./mL, whereas free Vol caused significant cytotoxicity (Fig. 1 G). These results confirm the biocompatibility, stability and cytotoxicity of TPVol.

Table 1: Characterization of TPVol obtained by post-modification at a Tf-DBCO/N3 molar ratio of 1.8/1.

| Entry | N3 Surface Density (mol.%) | Size (nm) | PDI | DLCa (wt.%) | DLEC (wt.%) |
|-------|---------------------------|-----------|-----|--------------|--------------|
| 1     | 48.1 ± 0.14 ± 0.03        | 5.0       | 52.1|
| 2     | 48.9 ± 0.15 ± 0.02        | 4.9       | 51.2|
| 3     | 49.4 ± 0.16 ± 0.03        | 5.1       | 53.5|
| 4     | 50.9 ± 0.16 ± 0.02        | 4.9       | 52.0|

a Measured by DLS using a Zetasizer Nano-ZS at 25 °C in PB (10 mM, pH 7.4).

b Determined by UV-vis measurements.

Fig. 1. (A) MALDI-TOF mass spectrometry of Tf and TF-DBCO. (B) Size distribution of TPVol and N3-PVol. (C) Stability of TPVol over 7-day storage at 4 °C or 10% FBS at 37 °C. (D) The viability of MV-4-11 cells after 72 h incubation with freshly made or stored TPVol. (E) Size change of TPVol in response to 10 mM GSH at 37 °C. (F) Hemolysis assay of mouse hemocytes after 3 h incubation with free Vol, PVol and TPVol. Pure water and Triton solution were as positive controls. (G) Cell viability of L929 fibroblasts following 4 h incubation with free Vol, PVol and TPVol and subsequent 6 h culture with drug-free medium. Statistical analysis: one-way ANOVA with Tukey multiple comparisons tests: *p < 0.05, **p < 0.001, ***p < 0.0001.

3.2. In vitro cellular uptake, cytotoxicity and blockage of PLK1 signaling

Transferrin receptors (TfR) are overexpressed on several malignant tumors in patients, and TfR-targeting nano-formulations have advanced to clinical trials for treating lung, breast and ovarian cancers [25,26]. TfR was also found highly upregulated in AML cells [18], and 57% AML patients overexpress TfR [27]. FACS analyses confirmed that MV-4-11 and U937 cell lines have high TfR expression while low TfR expression was observed on 697 cells (Fig. 1 A). Cellular uptake studies using Cy5-labeled TPVol and PVol showed clearly enhanced internalization of TPVol by MV-4-11 cells and TPVol with 4% Tf appeared to be the best (Fig. 2 B). CLSM images showed that TPVol and PVol caused significantly less hemolysis than free Vol and pure water, indicating excellent biocompatibility. MTT assays in L929 fibroblasts revealed that both TPVol and PVol were essentially non-toxic at a concentration of 40 μg Vol equiv./mL, whereas free Vol caused significant cytotoxicity (Fig. 1 G). These results confirm the biocompatibility, stability and cytotoxicity of TPVol.

Table 1: Characterization of TPVol obtained by post-modification at a Tf-DBCO/N3 molar ratio of 1.8/1.

| Entry | N3 Surface Density (mol.%) | Size (nm) | PDI | DLCa (wt.%) | DLEC (wt.%) |
|-------|---------------------------|-----------|-----|--------------|--------------|
| 1     | 48.1 ± 0.14 ± 0.03        | 5.0       | 52.1|
| 2     | 48.9 ± 0.15 ± 0.02        | 4.9       | 51.2|
| 3     | 49.4 ± 0.16 ± 0.03        | 5.1       | 53.5|
| 4     | 50.9 ± 0.16 ± 0.02        | 4.9       | 52.0|

a Measured by DLS using a Zetasizer Nano-ZS at 25 °C in PB (10 mM, pH 7.4).

b Determined by UV-vis measurements.
overexpressing U937 cells (Fig. 2D). For the inhibition experiments, in free Tf-pretreated MV-4-11 cells as well as in TfR low-expressing 697 cells, TPVol exhibited similar inhibitory activity to PVol (Fig. 2E and F). These results confirm the active targeting effect of TPVol toward MV-4-11 cells via TfR-mediated endocytosis, and Tf density plays an important role [28,29].

The apoptosis studies further revealed that TPVol and PVol treatment provoked 77.8% and 54.7% apoptosis of MV-4-11 cells, respectively, which were significantly higher than that for free Vol (14.9%) (Fig. 3A). Similar results were also observed in U937 cells (Fig. S4). The cell cycle assay displayed that TPVol induced obviously more cell arrest in G2/M phase than PVol and Vol (83% vs 61% and 45%) (Fig. 3B), illustrating the strong effect of PLK1 inhibition on cell cycle. PLK1 as a serine/threonine protein kinase is a master regulator of cell cycle progression, controls G2/M checkpoint [30,31], and is essential for tumor growth, such as DNA damage response. Using PLK1 as the target, onvansertib received FDA approval for treating KRAS mutant mCRC [32]. PLK1 expression was found high in several malignant cancers including AML [33–36]. The inhibition of PLK1 by volasertib would result in blocking of cell division and ultimately cell apoptosis [37]. We then evaluated the effect of Vol formulations on PLK1 signaling pathway in MV-4-11 cells (Fig. 3C&D). Western blot results disclosed that PLK1 expression had no big difference among groups, while p-PLK1 was significantly downregulated by TPVol indicating its strong deactivation effect against PLK1. TPVol treatment exhibited the most increased PTEN expression and decreased p-PTEN expression, as well as significantly down-regulated p-AKT, confirming our hypothesis (Scheme 1).

Collectively, enhanced cellular uptake of TPVol in TfR overexpressing cancer cells results in further downregulation of p-AKT and thereby augmented cytotoxicity and apoptosis compared to PVol and free Vol.

The anti-leukemic activity of TPVol was also studied in AML patient primary cells (Table S2) with various levels of TfR expression (Fig. 2A). The results showed that TPVol induced significantly more apoptosis of TfR overexpressing primary cells (#20210618) than PVol and free Vol, while in TfR low-expressing cells (#20210816 and #20200903) TPVol exhibited comparable apoptotic activity to free Vol (Fig. 2G, H&I, Fig. S5). The enhanced anti-leukemic activity of TPVol in TfR overexpressing cancer cells results in further downregulation of p-AKT and thereby augmented cytotoxicity and apoptosis compared to PVol and free Vol.

3.3. Pharmacokinetics and biodistribution of PVol and TPVol in mice

Encouraged by the excellent performance of TPVol in vitro, we then investigated the in vivo pharmacokinetics of TPVol in healthy Kunming mice using FITC-labeled Vol (Vol-FITC) as a model drug. Fig. 4A shows
that free drug was cleared rapidly showing an elimination half-life ($t_{1/2, \beta}$) of 2.5 h. While PVol and TPVol circulated prominently longer with $t_{1/2, \beta}$ of 12.9 and 10.7 h, respectively. The significantly increased AUC of PVol and TPVol compared with free Vol (Fig. 4B) illustrates the effective protection of Vol by polymersomes and little negative influence of Tf on the blood circulation of polymersomes. The longer circulation time compared with CD44-targeting polymersomes [42] may be attributed to the lower surface density of targeting ligands.

To investigate the tumor accumulation and anti-AML performance of TPVol in vivo, we built orthotopic AML model in NSG mice by irradiation with 175 cGy X-ray and 6 h later intravenous (i.v.) injection of MV-4-11-Luc-GFP cells ($1 \times 10^5$). The in vivo imaging showed that MV-4-11-Luc-GFP cells significantly infiltrated into bone marrow as from day 6 (Fig. 4C). The proportion of MV-4-11-Luc-GFP cells became very prominent on day 12, reaching 57.8%, 12.4% and 7.3% in BM, liver and spleen, respectively (Fig. 4D). This engraftment of MV-4-11 cells in the BM corroborates successful building of AML mouse model [43], as homing of leukemic cells in the BM is characteristic of AML patients [44]. Using such model, the accumulation of TPVol and PVol in the BM was visualized at 8 h post injection of Cy5-labeled TPVol or PVol. The ex vivo images of hind femurs and tibias and quantitative analyses (Fig. 4E and F) revealed significantly more TPVol than PVol in the BM (**p). Similar findings were reported in CD44-targeting polymersomes, indicating the potential of such polymersomes in AML treatment [45]. Moreover, TPVol group showed higher Cy5 fluorescence in BM than in other major organs (Fig. 4G), while liposomes with dual targeting ligands showed more accumulation in kidney and lung compared with bone marrow [46]. There was no much difference between TPVol and PVol in main organs, possibly due to the relatively low infiltration of AML cells other than BM. This enhanced accumulation of TPVol in the limb bones is likely a result of bone-homing feature of MV-4-11 cells (Fig. 4D) combined with targeting effect of TPVol to MV-4-11 cells.

3.4. In vivo therapeutic effect of TPVol in orthotopic AML model

To study the anti-AML performance of TPVol in orthotopic MV-4-11-Luc-GFP leukemic mice, on day 5 post-implantation of AML cells, free Vol, PVol or TPVol (Vol Conc: 0.07 μg/mL) was i.v. administrated every 2 days (Fig. 5A). The progression of MV-4-11-Luc-GFP tumor was monitored by using in vivo imaging. Fig. 5B shows that as compared to PBS group that had a quick augmentation of tumor bioluminescence and accumulation of leukemic cells in leg bones, all Vol formulations could repress tumor progression though to varying extents. Interestingly, PVol induced significantly better retardation of tumor progression than free Vol at 6 mpk (*p) and Tf targeting further enhanced the inhibitory effect (*p) (Fig. 5B&C). TPVol with 2% and 4% Tf exhibited similar anti-AML activity, in line with previous reports that 3.9% Tf density achieved optimal targeting effect [29]. Fig. 5D displays that PBS group gradually

![Fig. 3. The apoptosis assay (A), cell cycle assay (B) and western blot measurement (C, D) of MV-4-11 cells following 48-h incubation with free Vol, PVol or TPVol (Vol Conc: 0.07 μg/mL). Statistical analysis: one-way ANOVA with Tukey multiple comparisons tests: *p < 0.05, **p < 0.01, ***p < 0.001.](image-url)
lost body weight as a result of aggressive expansion of leukemic cells. In comparison, all Vol groups exhibited barely any body weight loss over the period of treatments, supporting effective suppression of tumor growth as well as little toxic effects of Vol formulations. It should be noted that human Tf was used in this study and how human Tf binds to mouse TfR expressed on the healthy organs and cells remained unclear. Whether the above toxicity results could reflect the situation in human requires further investigation.

MV-4-11 leukemia is an extremely malignant model, displayed short median survival time (MST) of 9 days (Fig. 5E). Free Vol and PVol at 6 mpk increased the MST to 12 and 15 days, respectively. Strikingly, both TPVol prolonged the MST to 22 days, which was significant improvement compared with PVol (**p) and highly significant over free Vol (****p) and PBS (**p). The above results confirm that TPVol possesses prominent targetability, enhanced anti-cancer potency, and good safety in MV-4-11-Luc-GFP leukemic model.

The anti-AML effect of 4%TPVol was further investigated at an increased dose of 9 mpk given every 3 days for total four injections. The results revealed markedly enhanced repression of tumor growth compared to TPVol at 6 mpk (**p) without causing apparent toxicity (Fig. 5B, C, D). Accordingly, the MST of MV-4-11-Luc-GFP leukemic mice was extended from 22 days at 6 mpk to 32 days (**p), which was 2.5 longer than PBS (MST = 9 days) (Fig. 5E). This improvement of survival benefits was also significant compared with recent reports with repeated administration of DO8/9 inhibitor and peptidomimetic MYB:CBP inhibitor for malignant leukemic models [47,48]. It should further be noted that unlike free Vol which induced bleeding at the injection site and required several minutes of pressing to stop bleeding, as a result of its platelet depleting effect and dose-limiting toxicity [49], TPVol and PVol stopped bleeding after 2–5 s of pressing. Hence, TPVol provides a novel dually targeted molecular therapy for AML, which not only remarkably improves the therapeutic effect and survival benefits but also reduces systemic toxicities.

### 3.5. Ex vivo evaluation of leukemia blast infiltration, PLK1 regulation and bone damage

To further investigate their anti-AML performance, we evaluated the effect of different Vol formulations on leukemia blast infiltration in BM and main organs, PLK1 regulation and bone damage of MV-4-11-Luc-GFP leukemic mice. The engraftment of MV-4-11-Luc-GFP leukemia blasts in the liver, spleen, BM and peripheral blood (PB) on day 9 was determined using FACS. Fig. 6 shows that PBS group had substantial proportions of leukemia blasts in BM (76.4%), liver (36.7%) and PB (9.1%), which were all dramatically reduced by treatments with Vol formulations. At the same dose of 6 mpk, TPVol resulted in considerably lowered proportions of AML cells in liver, spleen, BM and PB than PVol and free Vol. At an increased dose of 9 mpk, TPVol gave rise to barely detectable leukemia cells in liver, spleen, BM and PB. This effective mitigation of leukemia cells in the BM niche by TPVol is of particular importance, as most anti-AML therapies failed due to their inferior access to BM [43,50,51].

H&E staining images were taken to visualize the infiltration of AML cells into main organs. Fig. 7A shows enormous engraftment (A) and AUC (B) of FITC-labeled Vol, PVol and TPVol in healthy Balb/c mice. (C) In vivo bioluminescence images of NSG mice after i.v. injecting of MV-4-11-Luc-GFP cells on day 6 and 12, and (D) leukemia infiltration in bone marrow (BM), liver, and spleen on day 12. Ex vivo images of hind femurs and tibias (E) and main organs (F) at 8 h after injection of Cy5 labeled TPVol or PVol (day 12). (G) The semi-quantitative analyses of TPVol and PVol biodistribution. Statistical analysis: one-way ANOVA with Tukey multiple comparisons tests: ***p < 0.01.
blasts in BM. The p-AKT was more downregulated by different Vol formulations. As a matter of fact, p-AKT in PVol and TPVol groups was hardly detected (Fig. 7C). This marked reduction of p-AKT is due to combination of lessened leukemic blasts proportion in BM and effective suppression of p-AKT expression in leukemic cells by PLK1 inhibition.

To evaluate the effect of TPVol treatment to bone microenvironment, we analyzed the infiltration of osteoclasts using tartrate resistant acid phosphatase (TRAP) staining and bone damage to tibias and femurs using micro-compute tomography (μCT). TRAP images showed abundant osteoclasts (stained dark-red) in the femurs and tibias of PBS group, while little in those of TPVol groups (Fig. 8A). μCT images of tibias and femurs displayed obvious loss of trabecular structures for PBS and free Vol groups, clear improvement for PVol group, and significant recovery for two TPVol groups to similar level of healthy mice (Fig. 8B). The quantitative analyses of trabecular number (Tb.N), bone volume fraction (BV/TV), bone surface fraction (BS/BV), and trabecular spacing (Tb.sp) followed the same trend (Fig. 8C). It is worth noting that the mice treated with TPVol (9 mpk) had similar bone density as healthy mice and nearly intact trabecular tissue, in agreement with insignificant leukemia engraftment in BM and negligible osteoclast formation. These results corroborate that transferrin-guided polymersomes (TPs) can markedly augment the targetability, potency and safety of Vol to AML. The targeted nano-delivery of clinical molecular targeted drug appears to be a novel and attractive strategy to manage malignant AML.

4. Conclusion

We have demonstrated that Tf-functionalized polymersomes (TPs) enable robust loading and targeted delivery of a clinical molecular targeted drug, volasertib (Vol), to TfR-overexpressed AML cells in vivo, which can not only boost the specificity and anti-AML potency of Vol but also mitigate its systemic toxic effects. The therapeutic studies show that Vol-loaded TPs (TPVol) effectively deplete the leukemic cells in liver, spleen, bone marrow and peripheral blood in MV-4-11-Luc-GFP leukemic mice, leading to 2.5-fold longer median survival time than PBS with minimal bone damage. However, the AML mice were not completely cured, mainly due to remaining leukemic stem cells in the niche, which is the most important reason for AML relapse [47]. Further study may focus on co-delivery of drugs against cancer stem cells. Here, TPs are based on biodegradable polymers and with endogenous

---

**Fig. 5.** In vivo anti-AML efficacy of TPVol, PVol, and free Vol in orthotopic MV-4-11 leukemic mouse model (n = 7). (A) Workflow for building AML model and treating with different Vol formulations. The tumor bioluminescence images (B) and quantitative bioluminescence analyses (C) of MV-4-11 leukemic mice on day 0, 3, 6 and 9 after different treatments. Statistical analysis: one-way ANOVA with Tukey multiple comparisons tests: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. D) Relative body weight of the mice. (E) Kaplan-Meier survival curves. Statistical analysis: one-way ANOVA with Log-rank (Mantel-Cox) test, *p < 0.05.
Fig. 6. The representative FACS panels (A) and quantitative analyses (B) of leukemia burden in bone marrow (BM), liver, spleen, and peripheral blood (PB) of AML mice on day 9 after different treatments. One-way ANOVA with Tukey multiple comparisons tests: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Fig. 7. Ex vivo evaluation of leukemia blast infiltration and PLK1 regulation. (A) Representative H&E-stained images of liver and spleen slices. Yellow triangles point to the bleeding sites. Western blot (B) and quantitative analyses (C) of the cells collected from BM on day 9 after different treatments (n = 3). Scale bar: 50 μm. One-way ANOVA with Tukey multiple comparisons tests: *p < 0.05, **p < 0.01.
transferrin as a targeting ligand, rendering it a high potential for clinical translation. This targeted nano-delivery of molecular targeted drug provides a novel and unique strategy to combat AML.

Ethics approval and consent to participate

This study received approval from the ethics committee of the First Affiliated Hospital of Soochow University (Suzhou, P. R. China) (No. 2017169-2) and was conducted according to the principles of the Declaration of Helsinki. Informed consent was obtained from all participants.

CRediT authorship contribution statement

Yifeng Xia: Methodology, Investigation, Validation, Writing – original draft. Jingnan An: Investigation, Validation, Data curation. Jiayong Li: Investigation, Data curation. Wenxing Gu: Methodology, Validation. Yifan Zhang: Methodology, Validation. Songsong Zhao: Investigation. Cenzhu Zhao: Investigation. Yang Xu: Resources, Supervision. Bin Li: Resources. Zhiyuan Zhong: Conceptualization, Supervision, Writing – review & editing. Fenghua Meng: Conceptualization, Supervision, Writing – review & editing.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This work is supported by research grants from the National Natural Science Foundation of China (NSFC 52033006 and 82000157) and the Natural Science Foundation of Jiangsu Province (NO. BK20190173).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bioactmat.2022.08.032.

References

[1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA Cancer J. Clin. 70 (2020) 7–30, https://doi.org/10.3322/caac.21590.
[2] D.G.I. Cucchi, T.B. Polak, G.J. Ossenkoppele, C.A. Uyl-De Groot, J. Cloos, S. Zweegman, J.J.W.M. Janssen, Two decades of targeted therapies in acute myeloid leukemia, Leukemia 35 (2021) 651–660, https://doi.org/10.1038/s41375-021-01164-x.
[3] S. Horbacz, G. Gai, J. Lack, C.B. DeStefano, M.M. Gottesman, C.S. Hourigan, Heterogeneity in refractory acute myeloid leukemia, P. Natl. Acad. Sci. USA 116 (2019) 10494–10503, https://doi.org/10.1073/pnas.1902375116.
[4] G. Maschmeyer, J. De Greef, S.C. Mellinghoff, A. Nosari, A. Thiebaut-Bertrand, A. Bergeron, T. Franquet, N.M.A. Blieuhes, J.A. Maertens, Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECLI), Leukemia 33 (2019) 844–862, https://doi.org/10.1038/s41375-019-0386-z.
Bioactive Materials 21 (2023) 499–510

Y. Xia et al.

G. Casorati, P. Dellabona, M. Onozawa, T. Teshima, M. Griffioen, C.J.M. Halkes, J. H.F. Falkenburg, F. Stolzel, H. Allmann, M. Bornhauser, M. Waterhouse, R. Zeiser, J. Finke, N. Cleri, A. Bondanza, L. Vago, F. Cicci, C. Bonini, Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT, Nat. Commun. 10 (2019) 1065, https://doi.org/10.1038/s41467-019-08871-1.

[45] W. Gu, T. Liu, D. Fan, J. Zhang, Y. Xia, F. Meng, Y. Xu, J.J.L.M. Cornelissen, Z. Liu, Z. Zhong, A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+ acute myeloid leukemia, J. Contr. Release 329 (2021) 706–716, https://doi.org/10.1016/j.jconrel.2020.10.005.

[46] Y. Shi, Z. Su, S. Li, Y. Chen, X. Chen, Y. Xiao, M. Sun, Q. Ping, L. Zong, Multistep targeted nano drug delivery system aiming at leukemic stem cells and minimal residual disease, Mol. Pharm. 10 (2013) 2479–2489, https://doi.org/10.1021/mp4001266.

[47] D.C. Johnson, C.Y. Taabazuing, M.C. Okondo, A.J. Chui, S.D. Rao, F.C. Brown, C. Reed, E. Peguero, E. de Stanchina, A. Kentis, D.A. Bachovchin, DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia, Nat. Med. 24 (2018) 1151–1156, https://doi.org/10.1038/nmat4691.

[48] K. Ramaswamy, L. Forbes, G. Minuesa, T. Gindin, F. Brown, M.G. Kharas, A. V. Kvitsov, S.A. Armstrong, E. Still, E. de Stanchina, B. Knochel, R. Koche, A. Kentis, Peptidomimetic blockade of MYB in acute myeloid leukemia, Nat. Commun. 9 (2018) 110, https://doi.org/10.1038/s41467-017-02618-6.

[49] Y. Kobayashi, T. Yamauchi, H. Kiyoi, T. Sakura, T. Hata, K. Ando, A. Watabe, A. Harada, T. Taube, Y. Miyazaki, T. Naoe, Phase I trial of volasertib, a polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia, Cancer Sci. 106 (2015) 1590–1595, https://doi.org/10.1111/cas.12814.

[50] B. Kumar, M. Garcia, L. Weng, X. Jung, J.L. Murakami, X. Hu, T. McDonald, A. Lin, A.R. Kumar, D.L. DiGiusto, A.S. Stein, V.A. Pullarkat, S.K. Hui, N. Carlesso, Y. H. Kuo, R. Bhatia, G. Marucci, C.C. Chen, Acute myeloid leukemia microenvironment transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion, Leukemia 32 (2018) 575–587, https://doi.org/10.1038/leu.2017.259.

[51] H. Ågerstam, C. Karlsson, N. Hansen, C. Sandén, M. Askmyr, S. von Palffy, C. Högberg, M. Risdler, M. Wunderlich, G. Juliusson, J. Richter, K. Sjöström, R. Bhatia, J.C. Mulloy, M. Jarás, T. Fioretos, Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia, P. Natl. Acad. Sci. USA 112 (2015) 10786–10791, https://doi.org/10.1073/pnas.1422749112.